BPC-157 Significantly Reduces Post-Surgical Incisional Pain in Rat Model

Acute postoperative pain is a significant challenge in clinical practice, often managed with opioids that carry risks of addiction and side effects. There is a pressing need for effective, non-opioid alternatives that can promote healing while alleviating discomfort. BPC-157, a stable gastric pentadecapeptide, is known for its regenerative and anti-inflammatory properties, but its specific anti-nociceptive (pain-reducing) effects in acute incisional pain models have not been fully elucidated. This study addresses the knowledge gap regarding BPC-157's direct impact on pain perception and recovery following surgical incision.

The study found that BPC-157 significantly reduced pain-related behaviors compared to the saline control group. At 24 hours post-surgery, the BPC-157 treated rats showed a 43% reduction in mechanical allodynia scores (p<0.001) and a 35% increase in paw withdrawal latency during the hot plate test (p<0.01). This pain-relieving effect was sustained, with a 28% reduction in allodynia observed even at 72 hours. Histological examination revealed that the BPC-157 group exhibited 2.5-fold less inflammatory cell infiltration and 30% faster re-epithelialization at the incision site compared to controls (p<0.05). The most significant finding was the BPC-157 group's 2.5-fold increase in mechanical withdrawal threshold at 48 hours post-incision, indicating a substantial improvement in pain tolerance compared to the control group (p<0.001).